Amrinone-mediated thrombocytopenia.
Amrinone, a new cardioactive drug, was administered for, on average, 27.9 d to 12 patients in severe congestive heart failure. Thrombocytopenia occurred in 4 patients, while a progressive decline in platelet numbers developed in 3 additional patients. The mechanism for these adverse effects of amrinone is unclear, but merits further study because of its frequency.
D000631:Aminopyridines / Q000009:adverse effects* / Q000627:therapeutic use; D000676:Amrinone; D002316:Cardiotonic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006333:Heart Failure / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D010976:Platelet Count; D013921:Thrombocytopenia / Q000097:blood / Q000139:chemically induced*
D000631:Aminopyridines; D002316:Cardiotonic Agents; D000676:Amrinone